P127 Sphingosine-1-Phosphate Receptor Blockade with Etrasimod alters Lymphocyte Trafficking in Crohn's Disease: Insights from High-Dimensional Phenotypic Mapping

D Nikolakis,M J Pruijt,V E R Aberkrom,F A E de Voogd,D Branquinho,C Crosby,C Teichert,M G H van de Sande,J Grootjans,G R A M D'Haens
DOI: https://doi.org/10.1093/ecco-jcc/jjad212.0257
2024-01-01
Journal of Crohn's and Colitis
Abstract:Abstract Background The blockade of lymphocyte trafficking from the lymph nodes (LNs) towards the intestinal mucosa is an effective approach for the treatment of ulcerative colitis (UC). Etrasimod is an oral, once-daily (QD), selective sphingosine 1-phosphate (S1P)1,4,5 receptor (S1PR) modulator, which is currently also under investigation for Crohn’s disease (CD). The therapeutic mechanism of action of S1PR modulators in the context of inflammatory bowel disease (IBD) is not completely understood. It is hypothesized that both B and T- cell populations are affected by this treatment and are retained in the peripheral LNs, reducing circulating lymphocytes and resulting in fewer immune cells available to traffic in the gastrointestinal tract. Etrasimod has been reported to induce a partial and selective reduction of lymphocyte subsets in the blood of healthy subjects, but the direct effect of S1PR modulators on LN leukocytes has not been evaluated. The aim of this study was to investigate changes in leukocyte subpopulations in peripheral LNs and peripheral blood (PB) in response to S1PR inhibition with etrasimod in patients with CD. Methods CD patients with moderate to severe disease activity, participating in the Phase 2, double-blinded, non-placebo-controlled portion of the CULTIVATE trial, were eligible for this sub-study. At baseline and after 14 weeks of etrasimod induction treatment (2 or 3 mg/day), 10cc of PB and 4 ultrasound guided biopsy samples of an inguinal LN were obtained. The isolated peripheral blood mononuclear cells (PBMCs) and LN leukocyte populations, were analyzed at single cell level via high-dimensional immunophenotyping through mass cytometry (CyTOF) at both timepoints. Results We observed that in the LNs, the numbers/percentages of naïve, central and effector memory T-helper cells, as well as, of CD8+ naïve T-cells were increased after treatment with etrasimod. There was a decrease in the proportion of these cell populations in peripheral blood. Circulating naïve and memory B-cells were reduced, while these subsets where also slightly reduced in the LN compartment. Innate immune cell populations were not significantly altered. Conclusion Etrasimod induction treatment resulted in an increase of both naïve and central memory T-lymphocyte subsets in inguinal LNs, with a corresponding decrease in the periphery. The effect on the frequency of B-cells was not consistent in the LNs and PB, while innate immunotypes and T-regs, were not significantly affected. Despite the limited sample size, these selective effects were consistent with previously published PB immunophenotyping studies with etrasimod. This study was conducted as a collaboration between Amsterdam UMC and Pfizer.
gastroenterology & hepatology
What problem does this paper attempt to address?
This paper aims to explore the effect of Etrasimod on lymphocyte migration in patients with Crohn's Disease (CD). Specifically, researchers hope to analyze the changes in leukocyte subsets in peripheral lymph nodes (LNs) and peripheral blood (PB) after Etrasimod inhibits S1P receptors through high - dimensional phenotypic mapping (using mass cytometry, CyTOF). ### Research Background Blocking the migration of lymphocytes from lymph nodes to the intestinal mucosa is an effective treatment method for ulcerative colitis (UC). Etrasimod is an oral, once - daily selective S1P1,4,5 receptor modulator and is currently also under study for Crohn's disease. Although the treatment mechanism of S1P receptor modulators in inflammatory bowel disease (IBD) has not been fully understood, it is speculated that this treatment will affect the populations of B cells and T cells, causing these cells to be retained in peripheral lymph nodes, reducing the number of circulating lymphocytes, and thus reducing the number of immune cells available for intestinal migration. ### Research Objectives The main objective of this study is to evaluate the effect of Etrasimod on leukocyte subsets in peripheral lymph nodes and peripheral blood through S1P receptor inhibition. ### Main Findings - **Lymph Nodes**: After treatment, the number or percentage of naive T - helper cells, central memory T - helper cells, effector memory T - helper cells, and CD8 + naive T cells increased. - **Peripheral Blood**: The proportion of the above - mentioned cell populations decreased. - **B Cells**: Naive B cells and memory B cells in circulation decreased, and these subgroups also slightly decreased in peripheral lymph nodes. - **Innate Immune Cells**: No significant changes were observed. ### Conclusions Etrasimod - induced treatment leads to an increase in naive and central memory T - lymphocyte subsets in inguinal lymph nodes and a corresponding decrease in the periphery. The changes in B - cell frequency in peripheral lymph nodes and peripheral blood are inconsistent, while innate immune types and T - regulatory cells are not significantly affected. Despite the limited sample size, these selective effects are consistent with the previous results of peripheral blood immunophenotype studies on Etrasimod. This study was carried out in cooperation between Amsterdam UMC and Pfizer.